The YODA Project
Research Proposal Due Diligence Assessment

Part 1: General Information	
YODA Project (Protocol) ID:	2024-0688
Date:	16-July-2024
Product Name:	INVOKANA (Canagliflozin)
Therapeutic Area:	Cardiovascular & Metabolic Diseases
Product Class:	Diabetes Related – Other
Condition(s) Studied:	Diabetes Mellitus, Type 2
Protocol Number(s) and Title(s):	1. **NCT1032629 – 28431754DIA3008** – A Randomized, Multicenter, Double-blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus 2. **NCT1989754 – 28431754DIA4003** – A Randomized, Multicenter, Double-blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus,

Part 2: Data Availability	
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments:	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments:	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments:	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	

Part 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data are available for a data sharing request.	Yes

Part 4: Proposal Review	
Question:	**Response:**
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	